Royal Bank Of Canada Upgrades Cidara Therapeutics (NASDAQ:CDTX) to Moderate Buy
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) was upgraded by investment analysts at Royal Bank Of Canada from an “outperform” rating to a “moderate buy” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage presently has a $75.00 price objective on the biotechnology company’s stock, up from their previous price […]
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) was upgraded by investment analysts at Royal Bank Of Canada from an “outperform” rating to a “moderate buy” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage presently has a $75.00 price objective on the biotechnology company’s stock, up from their previous price […]
